When assessing aerodynamic particle size distribution (APSD) using the Next Generation Impactor (NGI), throat model selection can significantly influence drug deposition outcomes. Accurate deposition data is essential for optimising pMDI design and ensuring consistent, effective drug delivery to patients.
Recent research by our pulmonary/pMDI experts—Aaron Taylor, Chad Haraldson, and Stephen Stein at Kindeva—explores how United States Pharmacopeia (USP), oropharyngeal cast model (OPCM) and large volume chamber (LVC) inlets affect particle size measurements in HFA-152a solution pMDIs with varying ethanol concentrations.
Here were the key insights from the research:
- Inlet geometry drives deposition: The OPCM throat captured more large droplets, leading to lower fine particle fractions and artificially smaller measured MMADs.
- Ethanol concentration effects: As ethanol levels increased, throat deposition rose — most notably in the OPCM throat, which showed minimal sensitivity to ethanol changes compared to the USP inlet.
- LVC as a baseline: The 20L expansion chamber minimized throat interference, allowing a more accurate representation of initial droplet size and aerosol behavior.
This data underscores the importance of throat model selection in formulation development and in vitro characterization. Aligning test methods with real-world delivery dynamics improves product performance assessment and the relevance of in vitro data to clinical outcomes.
Want to dive deeper into the data? View the full poster presentation.
Contact us today to learn how Kindeva’s integrated expertise — from formulation and device development to testing and data analytics — is transforming tomorrow’s inhaled drug development.
Access this content
Fields marked with a * are required.
Related resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Career journeys blog 3: Lauren Harrison
In this story, we meet Lauren Harrison, a formulation scientist who began her path as an apprentice and has spent the last decade building a career rooted in curiosity, hands-on learning and collaboration.
Learn More
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade. In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares […]
Learn More
Beyond the contract: Driving transformational partnerships with manufacturing… and more
Achieving scientific breakthroughs is just one hurdle in today’s drug development and manufacturing process aimed at improving patient outcomes. Bringing a new therapy to market requires meticulous execution and clear communication at every step. Unfortunately, even the most groundbreaking scientific advancements can be delayed or even entirely abandoned due to poor performance from partners. This […]
Learn More
Why Kindeva: Analytical and regulatory services
Overcome complex analytical and regulatory challenges with a partner dedicated to your product’s success. Our specialist expertise helps you navigate testing, compliance, and quality to advance your project from concept to commercialization. Download our one-pager for a closer look at our integrated approach, including: An overview of our comprehensive, phase-appropriate analytical services. How our regulatory […]
Learn More
Career journeys blog 2: Oliver Ingham
In this latest installment, we meet Oliver Ingham, an analytical chemist whose curiosity and problem-solving skills have shaped his journey from academic research to coordinating analytical development services at Kindeva.
Learn More
Career journeys blog 1: Holly Dowdle
When Holly Dowdle first joined Kindeva as a student intern, she experienced a workplace that valued both curiosity and collaboration. It was an environment where asking questions was encouraged and development was part of everyday work, not something that happened on the sidelines.
Learn More
A bridge between design and delivery: Exploring sterile fill finish integration for injectable product success
The global sterile injectable contract manufacturing market is experiencing rapid growth, driven by increasing demand for advanced biologics, glucagon-like peptide-1 (GLP-1) therapies and other injectables. These products pair drugs with delivery devices to support patient-centric care, but their manufacturing presents unique challenges. Programs often require specialized environments, such as cold-chain storage and low-volume fills, and […]
Learn More
Going beyond manufacturing: The Kindeva customer experience
Going beyond manufacturing: The Kindeva customer experience As development timelines tighten and product complexity grows, the quality of CDMO partnerships has transformed into a critical success factor. In today’s high-stakes landscape, drug developers need more than technical execution. They need partners who embed early, stay aligned and help navigate every phase of the product lifecycle. […]
Learn More
Built for better tomorrows: How Bridgeton delivers for patients
Kindeva’s Bridgeton facility offers a purpose-built solution for the complex and evolving landscape of injectable drugs. The facility was specifically designed to address challenges in sterile injectable manufacturing, such as the siloed approaches that often separate core functions like formulation and fill finish. By co-locating these functions and operating within integrated systems, the Bridgeton model […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.